NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,169.30
- Market cap
- ₹52,297 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 42.3×Sector 43.0×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹18,336 Mn (+23% YoY), PAT ₹2,908 Mn (+58%), adj. EBITDA margin 27%. US CDMO and launches lead; India and RoW weak.
Gland Pharma Results Update
Gland Pharma reported Q2FY27 revenue of Rs. 18,336 Mn, up 23% YoY, and PAT of Rs. 2,908 Mn, up 58% YoY. The press release accompanies its quarterly financial results filing.
Gland Pharma Q2 FY27 Results: Net Profit ₹290.8 Cr, Up 58.3% YoY
Gland Pharma Ltd reported revenue from operations of ₹1,834 Cr (+23.3% YoY) and net profit of ₹290.8 Cr (+58.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹290.8 Cr · +58.3% YoY
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.
Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Other annual general meeting announcements
All →Meesho Annual General Meeting
Meesho seeks postal ballot approval, with voting closing 08-Dec-2026, to appoint Sudhir Sitapati as Independent Director. The resolution also covers ₹1 Crore annual remuneration.
Indrayani Biotech Annual General Meeting
Indrayani Biotech's 34th AGM is set for 30 November 2026, with book closure from 24 to 30 November. Remote e-voting runs 27 to 29 November 2026.
Kirloskar Ferrous Industries Annual General Meeting
Kirloskar Ferrous shareholders approved Ajay Shriram Patil's appointment as Director and Joint Managing Director via postal ballot. Both ordinary resolutions passed with over 98% votes in favour.
HDFC Bank Annual General Meeting
HDFC Bank's postal ballot passed the appointment of Anup Bagchi as Managing Director and CEO. Approval was deemed on 6 November 2026 with 98.646% votes in favour.
Britannia Industries Annual General Meeting
Britannia shareholders passed the special resolution appointing Sonny Iqbal as Non-Executive Independent Director via postal ballot. Approval was 99.7187% in favour of votes polled.
Asian Paints Annual General Meeting
Asian Paints shareholders approved Leo Puri's appointment as Independent Director via postal ballot. Voting results and the scrutinizer's report were filed.